

Review Article

Open Access

The Relationship between Triiodothyronine and Thyroid Stimulating Hormone Serum Level into Melasma Severity

Frien Refla Syarif*, Sri Lestari and Satya Wydya Yenny

Dr. M. Djamil Hospital, West Sumatera, Indonesia

ABSTRACT

Background: Melasma is a chronic acquired hypermelanosis of the skin and relatively common skin disorder that primarily affects sunlight-exposed areas in women. While etiology of melasma is not yet well understood, a possible factor is thyroid hormones. Few studies have been conducted in order to find the relationship between melasma and thyroid disorders with varying results. This study is conducted to investigate the association between thyroid parameters (triiodothyronine and thyroid stimulating hormone) and melasma severity.

Aim: To determine the relationship between triiodothyronine (T3) and thyroid stimulating hormone (TSH) serum level into severity of melasma.

Subject and method: Thirty six women with melasma aged >18 years old are included in the study group indoor at Dr. M. Djamil Hospital Padang. Exclusion criteria: pregnancy/lactation, using oral contraception, using hormonal therapy, taking photosensitizer systemic antifungi and anticonvulsant and taking topical/systemic of melasma treatment. History of sun protection usages and MASI score are recorded. Triiodothyronine and TSH level are measured by electrochemiluminescence-immunoassay (ECLIA) method.

Result: Mean age of melasma patients in this study: 47.52±8.11 years old. Malar type is more common than centrofacial (61,1%) and we did not find mandibular type. The most common severity of melasma: mild (19 out of 36 people). MASI score: 21.46±10.40. Mean serum level of T3 and TSH: 1.578±0.282 nmol/L and 1.773±1.457 µIU/L (p>0,05).

Conclusion: Mean serum levels of T3 and TSH hormones are not related to the severity of melasma. Nevertheless, increasing levels of hormones are in accordance with the increase of melasma's severity degree, although it is not statistically significant. Further study could be done by adding hypothyroidism to patients who have melasma and comparing them with control group by using cross-sectional comparative sampling. An equal sample number of each severity degree of melasma would be ideal and then evaluate psychological/stress factors to the subjects.

*Corresponding author

Frien Refla Syarif, Dr. M. Djamil Hospital, West Sumatera, Indonesia. dr.refla.syarif@gmail.com

Received: June 02, 2021; **Accepted:** June 23, 2021; **Published:** July 31, 2021

Keyword: Triiodothyronine Hormone, Thyroid Stimulating Hormone, Melasma Severity.

Introduction

Melasma is an acquired hypermelanosis with irregular lesion, colored from light to dark brown, on sun-exposed areas. The lesion could appear either on the upper lip, nose, cheeks, chin, forehead, sometimes on the neck, chest and the dorsal arm. Melasma is usually shaped irregularly, often demarcated, with bright to brown-black pigmentation.

Melasma is epidemiologically found in all races. Based on available data, it is found more often on women rather than men. As much as 90% of the cases are found in people with an age range of 30 to 50 years old, but the exact number is unknown. Melasma is often found in tropical countries, including Indonesia, with a varying incidence rate in different spectrums of population. Melasma prevalence in Southeast Asia reaches 40% in female and 20% in male. Incidence rate of melasma in women during 2012-2014 at the Dermato-Venereology Outpatient Clinic of Dr.

M. Djamil Hospital Padang is 129 (0.095%) out of 1,355 patient visits to the Division of Cosmetic Dermatology (non-publication). The etiology of melasma is not yet known for certain, but there are several factors that play a role in melasma pathogenesis such as exposure to ultraviolet radiation, genetic predisposition, pregnancy, oral contraceptives, hormone replacement therapy, cosmetics, phototoxic medications, anticonvulsant drugs and endocrine factors associated with thyroid disorders. Thyroid disorder is known to involve the entire organ system of the body and the skin is no exception. Both hyperthyroidism and hypothyroidism cause changes to structure and function of the skin.

Assessment levels of T3 and TSH serum is a useful indicator to determine the status of clinical hypothyroidism as TSH serum concentration is a sensitive indicator of thyroid dysfunction. If the thyroid function is abnormal, TSH serum level will change even under subclinical conditions. Thyroid stimulating hormone serum levels that exceed 2.5 µIU/mL is referred as subclinical hypothyroidism. Hypothyroidism is clinically defined as endocrine status with a value of TSH> 4.0 µIU/L; T3<1.2 nmol/L. The

relationship between thyroid hormone and the incidence rate of melasma has long been studied, but the relationship between them is very complex and there is only limited research.

Subjects and Methods

This study is an observational analytic study with a cross-sectional design. It is conducted at the Division of Cosmetic Dermatology of Outpatient Clinic of Dr. M. Djamil Hospital Padang and the Regional Health Laboratory Padang. Subjects of research are patients with a diagnosis of melasma who come to the Division of Cosmetic Dermatology of Outpatient Clinic and worked at Dr. M. Djamil Hospital Padang. The study is approved by the the Faculty of Medicine Ethics Committee, Andalas University Padang.

The number of samples are determined by a sampling quota method based on a specified number. The specified number of samples in this study are 36 people who has been verified through the inclusion and exclusion criteria. The study is conducted from January to May 2016.

Inclusion and exclusion criteria

Inclusion criteria: women with melasma aged >18 years old, working indoor between 9am to 3pm local time and willing to participate in the study by signing an informed consent after being given an explanation of the study. Exclusion criteria: pregnant and nursing women, taking oral contraceptives, received hormonal therapy, taking systemic antifungal (griseofulvin) or photosensitiser medication (amiodarone, tetracycline, minocycline, chloroquine, cytostatics such as cyclophosphamide, 5-flourouracil, doxorubicin, daunorubicin and bleomycin, heavy metals, inorganic arsenic), treated by anticonvulsants (hydantoin, dilantin, phenytoin, phenothiazines, chlorpromazine, levodopa and barbiturates) and in treatment of melasma (topical and/or systemic).

Informed consent

All patients are required to provide a written informed consent for participation in the study.

Study Assessments

All patients are assessed for demographics including age, clinical distribution of melasma, melasma severity degree and MASI score. Patients are examined to identify their distribution of melasma which is divided into three regions: centrofacial (cheeks, forehead, upper lip, nose and chin), malar (cheeks and nose) and mandibular (ramus of the mandible). All the patients are examined by a certified dermatologist.

Data collection

The data of all patients are collected in study protocol report forms and are saved to computer using Microsoft Excel for review.

Statistical Analysis

The mean age of all patients is calculated using observational analytic statistics. One-way analysis of variance (ANOVA) is performed to determine statistical difference in T3 and TSH mean value. The mean value of T3 and TSH to melasma severity (for each degree of melasma) is obtained and evaluated for statistical significance using one-way ANOVA. A p<0.05 is considered as statistically significant.

A total of 36 female patients (ranged from 27 to 56 years old) with mean age of 47.52±8.11 years old suffering from melasma are included in the study. Observation at pattern of clinical features mostly found malar type in 22 (61.1%) while no mandibular type found on research subjects. Based on the severity of melasma, mild degree is mostly found in 19 people (52.8%). The mean value MASI scores in this study is 21.46±10.40 (table 1).

Table 1

Characteristic	f (n = 36)	p (%)
Age		
15 – 19 year-old	0	0
20 – 24 year-old	0	0
25 – 29 year-old	1	2,7
30 – 34 year-old	4	11,1
35 – 39 year-old	1	2,7
40 – 44 year-old	3	8,3
45 – 49 year-old	9	25
> 50 year-old	18	50
Mean ± standard deviation	47,52 ± 8,11 year-old	
Pattern of clinical features		
Malar	22	61,1
Centrofacial	14	38,9
Mandibular	0	0
Severity		
Mild	19	52,8
Moderate	12	33,3
Severe	5	13,9
MASI Score	Mean Value	
Mild	13,15	
Moderate	27,54	
Severe	38,42	
Mean ± standard deviation	21,46 ± 10,40	

The mean value levels of T3 and TSH in severe degree of melasma is higher (1.605±0.309 and 2,4±1,158) compared to mild and moderate degree. As seen in each degree, there is an increasing mean value of T3 and TSH (table 2).

Table 2

Melasma Severity	Mean value of T3 serum level (nmol/l)	Mean value of TSH serum level (µIU/L)
Mild	1,572 ± 0,340	1,607 ± 1,723
Moderate	1,574 ± 0,169	1,776 ± 1,089
Severe	1,605 ± 0,309	2,4 ± 1,158

Relationship between T3 and TSH serum level to the severity of melasma as analysed using ANOVA statistical test does not find a significant association between mean value of T3 and TSH serum levels to the severity of melasma (1.578±0.282 nmol/L and 1.773±1.457 µIU/L; p>0.05) (table 3).

Table 3

Melasma Severity	Mean value of T3 serum level (nmol/l)	p value	Mean value of TSH serum level (μIU/L)	p value
Mild	1,572	1,000	1,607	1,000
Moderate	1,574	1,000	1,776	1,000
Severe	1,605	0,085	2,400	0,879
Mean ± standard deviation	1,578 ± 0,282	0,975	1,773 ± 1,457	0,571

Discussion

Mean age of patients suffering from melasma the study is 47.52±8.11 years old. Epidemiologically, mean age of patients suffering from melasma in women is aged between 30 and 50 years old. Mean age of patients in this study therefore corresponds to the epidemiology of melasma.

Based on age, T3 hormone levels is reduced at an older age due to secretion of thyroid hormone T3. Although TSH level is relatively stable between 40 and 50 years old, it can be decreased or increased through iodine intake. In case of decreasing level of TSH, it is caused by the increasing sensitivity of pituitary gland to decrease circulating thyroid hormones and TSH secretion. As the secretion of hormones T3 and TSH are influenced by age, in normal circumstances despite T3 hormone declines with increasing age, TSH can either decrease or increase. In this study, mean age of patients suffering from melasma is in the range of epidemiological age (between 30 and 50 years old). Therefore, it can be concluded that in this study, age does not affect the level of hormones T3 and TSH.

The pattern of clinical feature malar type is found in 22 patients (61.1%). There is no mandibular type in this study because of mandibular type is rarely found (16%). Melasma is more commonly found on sun-exposed areas such as forehead, nose, cheeks, chin and upper lip, whereas the mandible area is rarely exposed to sun.

Indonesia is a tropical country, where it is exposed to the sun with strong enough intensity almost all year long. In countries with 4 seasons, people with melasma are more prevalent in the summer and appear to be less in winter. This shows the magnitude of relationship between the severity of melasma and sun exposure. Based on theories and research results that are previously discussed where T3 and TSH hormone levels are lower in the summe and Indonesia is a tropical country with strong intensity of exposure to the sun, it can be concluded that the patttern of clinical feature of melasma is greatly influenced by the ultraviolet where the malar and centrofacial type are found in this study. However, since the whole subject of research is worked indoor and not exposed to sunlight at peak time (between 10am and 2pm), it can be concluded that exposure to sunlight does not affect thyroid hormone level on the subjects of this study.

Results of melasma severity mostly found to be mild in 19 (52.8%) out of 36 people. According to the reviews mentioned by Handel AC, et al. (2014) patients who have melasma are often more motivated to go to a dermatologist. Cestari T, et al. (2006) examine 300 patients suffering from melasma with a result of 65% patients report feeling discomfort because of patches on their face, 55% feeling frustrated and 57% feeling ashamed of the disease. This is because melasma appears mainly on the face, although mild, do often cause cosmetic and psychological problems. Women, especially, in turn will quicky go to a dermatologist.

The mean value of MASI score is 21.46±10.40. Validity testing shows that the MASI score is able to provide precise estimation of on melasma severity. Total MASI score on mild degree is <24, moderate is if the total score is between 25 and 36, whilst severe is if the total score is between 37 and 48. Triiodothyronine hormone level affects the degradation of melanosomes at the time of melanin transfer to keratinocytes and their resilience in kreatinocytes, whereas TSH affects the amount of melanin in melanogenesis. The mean proportion of the number of samples in each degree of melasma is not equal where mild degree has the most subjects (19 people/52.8%).


The distribution of mean value of T3 and TSH serum level is in the normal range (1.605±0.309 and 2.4±1.158). The mean value result of the two hormones are relatively normal. It might be caused by the compensation of endocrine hormones' negative feedback loop in the thyroid gland pituitary. Table 2 shows an increase in T3 and TSH serum levels due to the severity of melasma.

TSH serum level that exceed 2.5 μIU/L is referred as subclinical hypothyroidism. Hypothyroidism is clinically defined as endocrine status with a value of TSH > 4.0 μIU/L and T3 < 1.2 nmol/L. Normal TSH value is ranged from 0.5 to 4.0 μIU/L and T3 from 1.2 to 1.8 nmol/L. T3 and TSH serum levels are useful indicators for determining the status of hypothyroidism. Clinical concentration of TSH serum is a sensitive indicator of dysfunction tiroid.

Melasma is the result of hyperactivity of local dermal-epidermal melanin unit resulting in hypermalanisation. Epidermal hypermalanisation is influenced by thyroid hormones. Hypothyroidism occurs in the case where melanogenesis and intact of melanosomes epidermis increase. In case of hypothyroidism, the levels of T3 and T4 are decreasing and a negative feedback loop on the hypothalamus and the pituitary gland of the brain activate and stimulate the formation of TRH. TSH level then increases and produces pro-hormones T4 and the active from T3.

Research on the relationship between melasma and thyroid hormone has been carried out for years. Perez M, et al. (1983) found a link between hormone in the incidence of melasma, but the data obtains many conflicting views possibly due to various genetic backgrounds on study populations. On the other hand, the relation between thyroid hormone abnormalities and the incidence of melasma has not yet been reported much. Handel AC, et al. (2014) states there is no strong evidence to support a connection between thyroid abnormalities to melasma and melasma or thyroid disease even though it is very common in women.

Statistic analysis result using ANOVA test in this study found no significant relationship between the mean value of T3 and TSH hromosome levels to the severity of melasma. Even so, mean value of both hormones in each of the severity degree of melasma is associated with an increase to the severity of melasma (graphic 1).



Graphic

Aetiopathogenesis melasma that has not been evaluated by the researcher is the emotional stress factors. There have been case reports of melasma that is obtained onset after an episode of emotional stress and affective disorders (e.g. depression). Level of stress on a person can be described as interference or may cause physiological and psychological malfunctioning to someone. Stressor can come from outside the human body (external stressor) and internal stressor (associated with genetic factors, development and growth). External stressors can be measured using a scale, the one that is used is the Holmes scale. The scale that is used to measure the level of an external stressor which the questions are given is a general perception that could potentially cause stress on the subjects.

Several studies that prove stress affects the skin through neruopeptidergic peripheral nerve fibers and exacerbates beurogenic aspect because melanocytes is derived from the neural crest. This explains why the melanocytes in human skin has been linked with neural fibers. Some hormones that activate the melanocortin receptor that induces melanogenesis which are propiomelanocortin, adrenocorticotropin hormone (ACTH) and melanocyte stimulating hormone (MSH), of which are related to stress. Besides affecting melanogenesis, hormone level changes in response to stress, one of the hormones that are affected by stress conditions is thyroid hormone. Thyroid function usually is down-regulated during stressful conditions. Triiodothyronine and tyroxine levels is decreased in a state of stress. Stress inhibits the secretion of TSH as the action of glucocorticoids on the central nerveous system. Verma K, et al. (2016) in their study shows 40.9% of the total 66 study subjects had a history of stress and emotional factors before contracts melasma.

We did not assess the emotional stress factors on the subject of research. The status of hypothyroidism in this study subjects to melasma studied is not homogeneous. It is expected for further research to get the subject of research number equally to each degree of melasma severity, homogeneous status of hypothyroidism in melasma patients and assess the emotional stress factors to get significant relationship between T3 and TSH serum level to melasma severity.

Conclusion

The result of this study shows that mean levels of both T3 and TSH serum in melasma patients are relatively normal, nevertheless increasing level of both hormones are in accordance with an increase in the severity of melasma. Further study can be done to larger subjects by adding the inclusion criteria of melasma patients with hypothyroidism and comparing them to control patients without hypothyroidism using cross-sectional comparative sampling and assess the stress factors using a scale to get more significant results [1-127].

Conflict of interest

I declare that there are no conflict of interests regarding the publication of this paper.

References

1. Lapeere H, Boone B, Schepper SD, Verhaeghe E, Gele MV, Ongenaes K, (2012) et al. Hypomelanoses and hypermelanoses. In: Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffel DJ, Wolff K, eds. Fitzpatrick's dermatology in general medicine, New York: Mc Graw Hill 1: 804-826.
2. Trout CR, Levine N, Chang MW (2004) Disorders of pigmentation. In: Bologna JL, Jorizzo JL, Rapini R, editor. *Dermatology* 1: 975-1004.
3. Soepardiman L, Kelainan pigmen (2007) In: Djuanda A, Hamzah M, Aisah S, editors. *Ilmu penyakit kulit dan kelamin*. 5th ed. Jakarta: FKUI 289-299.
4. Rizal Y, Lestari S (2008) Insidens melasma di Poli Kulit dan Kelamin RSUP Dr. M.Djamil Padang tahun 2001-2006. *Media Dermato-Venereologica Indonesiana* 35: 56-59.
5. James WD, Berger TG, Elston DM (2011) Disturbances of pigmentation. In: James WD, Berger TG, Elston DM, eds. *Andrews' disease of the skin clinical dermatology*. 11th ed. New York: WB Saunders Comp 843-862.
6. Rendon M, Berneburg M, Arellano I, Picardo M (2006) Treatment of melasma. *Journal of the American Academy Dermatology* 54: S272-281.
7. Pinto JM, Borges MDFM, Magalhaes GM (2006) A review of melasma, part 1: Ethiopathogenic factors, clinical and histopathologic evaluations. *Cosmetic Dermatology* 19: 683-687.
8. Jimbow K, Jimbow M (1989) Pigmentary disorders in oriental skin. *Clinico Dermatology* 7: 11-27.
9. Taylor SC (2003) Epidemiology of skin diseases in people of color. *Highlighting Skin of Color* 71: 271-275.
10. Sheth VM, Pandya AG (2011) Melasma: A comprehensive update part I. *Journal of the American Academy Dermatology* 65: 689-697.
11. Shankar KDSR, Somani VK, Kohli M, Sharad J, Ganjoo A, (2014) et al. A cross-sectional, multicentric clinico-epidemiological study of melasma in India. *Dermatologic Therapy* 3: 71-81.
12. Goh CL, Dlova CN (1999) A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral center in Singapore. *Singapore Medical Journal* 40: 455-458.
13. Almosuly IM, Butros RO (2010) Clinical assessment of melasma in patients attending the Department of Dermatology and Venereology at Rizgary Teaching Hospital in Erbil City. *Zanco Journal of Medical Sciences* 14: 55-60.
14. Parsad D, Kumarasinge PW (2006) Psycho-social implications of pigmentary disorders in Asia. *Journal of Investigative Dermatology* 1-8.
15. Walker C (2005) Skin disease and psychology: A multitude of links. In: Walker C dan Papadopoulos L, editors. *Psychodermatology the psychological impact of skin disorders*. New York: Cambridge University Press, Cambridge 1-14.
16. Doward LC, McKenna SP (1998) Evolution of quality assessment. In: Rajagopalan R, Sheretz EF, Anderson TR, editors. *Care management of skin disease*. New York: Marcell-Dekker 9-94.
17. Ali R, Aman S, Nadeem M, Kazmi AH (2013) Quality of life in patients of melasma. *Journal Pakistan of Dermatologists* 23: 143-148.
18. Pawaskar MD, Parikh P, Markowsky T, McMichael AJ, Feldman SR, et al. (2007) Melasma and its impact on health-related quality of life in Hispanic women. *Journal of Dermatology Treatment* 18: 5-9.
19. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, et al. (2003) Development and validation of a health-related quality of life instrument for women with melasma. *British Journal of Dermatology* 149: 572-577.
20. Steiner D, Feola C, Bialeski N, Silva FAM (2009) Treatment of melasma: Systematic review. *Surgical & Cosmetic Dermatology* 1: 87-94.
21. Shweta K, Khozema S, Meenu R, Anupama S, Singh SK, et al. (2011) A systemic review on melasma: A review. *International Journal of Current Bio Medical Sciences* 1: 63-68.

22. Cranenburgh OD, Prinsen CAC, Sprangers MAG, Spuls P, Korte JD. (2012) Health-related quality of life assessment in dermatologic practice: Relevance and application. *Dermatologic Clinics* 30: 323-332.
23. Yazdanfar A, Hashemi B (2010) Association of melasma with thyroid autoimmunity: A case-control study. *Iranian Journal of Dermatology* 13: 51-53.
24. Odom RB, James WD, Berger TG (2011) Disturbances of pigmentation. In: James WD, Berger TG, Elston DM, eds. *Andrew's diseases of the skin*, 11th ed. Philadelphia: WB Saunders-Elsevier Company 846-862.
25. Achar A, Rathi SK (2011) Melasma: A clinico-epidemiological study of 312 cases. *Indian Journal of Dermatology* 56: 380-382.
26. Dogra A, Dua A, Singh P (2006) Thyroid and skin. *Indian Journal of Dermatology* 51: 96-99.
27. Dogra A, Dua A (2006) Cutaneous changes in hypothyroidism. *Thyroid Research and Practice* 3: 45-49.
28. Haritha S, Sampath K (2013) Skin manifestation of hypothyroidism – a clinical study. *Journal of Dental and Medical Sciences* 7: 58-60.
29. Malek ZAA, Kadekaro AL (2010) Human cutaneous pigmentation. *Physiological Regulation of Human Cutaneous Pigmentation* 11: 81-100.
30. Solano F (2014) Melanins: Skin pigments and much more types, structural models, biological functions, and formation routes. *New Journal of Science* 6: 1-28.
31. Dentice M, Salvatore D (2011) Deiodinase: The balance of thyroid hormone: Local impact of thyroid hormone inactivation. *Journal of Endocrinology* 209: 273-282.
32. Safer JD (2011) Thyroid hormone action on skin. *Dermato-Endocrinology* 3: 211-215.
33. Paus R (2010) Exploring the “thyroid-skin connection”: Concepts, questions, and clinical relevance. *Journal of Investigative Dermatology* 130: 7-10.
34. Bodo E, Kany B, Gaspar E, Knuver J, Kromminga A, et al. (2010) Thyroid-stimulating hormone, a novel, locally produced modulator of human epidermal functions, is regulated by thyrotropin-releasing hormone and thyroid hormones. *Endocrinology* 151: 1633-1642.
35. Zouboulis CC (2004) The human skin as a hormone target and an endocrine gland. *Hormones* 3: 9-26.
36. Jurado CC, Serrano LG, Ferreria MG, Costa C, Paramio JM, et al. (2011) The thyroid hormone receptors as modulators of skin proliferation and inflammation. *Journal of Biological Chemistry* 286: 24079-24088.
37. Kasraee B (2002) Depigmentation of brown Guinea pig skin by topical application of methimazole. *The Journal of Investigative Dermatology* 1: 205-207.
38. Mullin GE, Eastern JS (1986) Cutaneous consequences of accelerated thyroid function. *Cutis* 37: 109-114.
39. Kasumagic HE (2014) Thyroid disease and the skin. *Annals of Thyroid Research* 1: 27-31.
40. Park KC, Huh SY, Choi HR, Kim DS (2010) Biology of melanogenesis and the search for hypopigmenting agents. *Dermatologica Sinica* 28: 53-58.
41. Choi HI, Sohn KC, Hong DK, Lee Y, Kim CD, et al (2014) Melanosom uptake is associated with the proliferation and differentiation of keratinocytes. *Archives of Dermatological Research* 306: 59-66.
42. Videira IFS, Magina S, Moura DFL (2013) Mechanism regulating melanogenesis. *Anais Brasileiros de Dermatologia* 88: 76-83.
43. Ebanks JP, Koshoffer A, Wickett RR, Schwemberger S, Babcock G, et al. (2011) Epidermal keratinocytes from light vs. dark skin exhibit differential degradation of melanosomes. *Journal of Investigative Dermatology* 131: 1226-1233.
44. Ebanks JP, Wickett RR, Boissy RE (2009) Mechanism regulating skin pigmentation: The rise and fall of complexion coloration. *International Journal of Molecular Sciences* 10: 4066-4087.
45. Grando SA (1993) Physiology of endocrine skin interrelations. *Journal of the American Academy of Dermatology* 28: 981-992.
46. Kasraee B, Hugin A, Tran C, Sorg O, Saurat JH (2004) Methimazole is an inhibitor of melanin synthesis in cultured B16 melanocytes. *The Journal of Investigative Dermatology* 12: 1338-1341.
47. Barrett EJ (2003) The thyroid gland. In: Boron WF, Boulpaep EL, eds. *Medical physiology. A cellular and molecular approach*. 1st ed. Philadelphia: Saunders 1035-1048.
48. Chiamolera MI, Wondisford FE (2009) Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. *Endocrinology* 150: 1091-1096.
49. Gaspar E, Nguyen-Thi KT, Hardenbicker C, Tiede S, Plate C, et al. (2011) Thyrotropin-releasing hormone selectively stimulates human hair follicle pigmentation. *Journal of Investigative Dermatology* 131: 2368-2377.
50. Slominski A (2009) Neuroendocrine activity of melanocyte. *Experimental Dermatology* 18: 760-763.
51. Tsygankova OM, Saavedra A, Rebhun JF, Quilliam LA, Meinkoth JL (2001) Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. *Molecular and Cellular Biology* 21: 1921-1929.
52. Zanni MSG, Campana R, Papa M, Ragazzini L, Monetti E, et al. (2008) Cutaneous manifestation in hypothyroid patients. *Clinica Universitaria Reina Fabiola* 2: 1-4.
53. Antonini D, Sibilio A, Dentice M, Missero C (2013) An intimate relationship between thyroid hormone and skin: Regulation of gene expression. *Frontiers in Endocrinology* 4: 1-9.
54. Sugimoto K, Mori K (2012) Thyroid-stimulating hormone regulation and transcription in hypothyroidism. *Influences and Treatments Intechopen* 15: 255-276.
55. Guarneri F (2014) Etiopathogenesis of melasma. *Pigmentary Disorders S1*: 1-5.
56. Talaee R, Ghafarpassand I, Masror H (2015) The relationship between melasma and disturbances in the serum level of thyroid hormones and indices. *Medicine Journal* 2: 19-23.
57. Luthfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzales EA, et al. (1985) Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. *Journal of Clinical Endocrinology & Metabolism* 61: 28-31.
58. Kiani A, Ahmari M, Rezvan FMR (2006) Association of melasma with thyroid disorders: A case-control study. *Iranian Journal of Dermatology* 9: 154-158.
59. Niepomnische H, Amad H (2001) Skin disorders and thyroid diseases. *Journal of Endocrinological Investigation* 24: 628-638.
60. Kavya M (2014) Melasma: A clinico-epidemiological study. *International Journal of Basic and Applied Medical Sciences* 4: 388-391.
61. Mogaddam MR, Alamdari MI, Maleki N, Ardabili NS, Abedkouhi S (2015) Evaluation of autoimmune thyroid disease in melasma. *Journal of Cosmetic Dermatology* 0: 1-5.
62. Taylor SC (2007) Objective and subjective measures of melasma. *Cosmetic Dermatology*. 2007 20: 93-95.
63. Taylor S, Westerhof W, Im S, Lim J (2006) Noninvasive techniques for the evaluation of skin color. *Journal of the*

- American Academy Dermatology 54: S282-290.
64. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, et al. (2011) Reliability assessment and validation of the melasma area and severity index (MASI) and a new modified MASI scoring method. *Journal of the American Academy Dermatology* 64:78-83.
 65. Treerichod A, Chansakulporn S, Wattanapan P (2014) Correlation between skin color evaluation by skin color scale chart and narrowband reflectance spectrophotometer. *Indian Journal of Dermatology* 59: 339-342.
 66. Damevska K (2014) New aspects of melasma. *Serbian Journal of Dermatology and Venereology* 6: 5-18.
 67. Handel AC, Miot LDB, Miot HA (2014) Melasma: A clinical and epidemiological review. *Anais Brasileiros de Dermatologia* 89: 771-782.
 68. Werlinger KD, Guevara IL, Gonzales CM, Rincon ET, Caetano R, et al. (2007) Prevalence of self-diagnosed melasma among pre-menopausal Latino women in Dallas and Forth Worth Tex. *Archives of Dermatology* 143: 424-425.
 69. Sanchez MR (2003) cutaneous disease in Latinos. *Dermatological Clinics* 21: 689-697.
 70. Ishiy PS, Silva LR, Penha MA, Handel AC, Miot HA (2014) Skin diseases reported by workers from the campus UNESP Rubiao Jr, Botucatu-SP (Brazil). *Anais Brasileiros de Dermatologia* 89: 529-531.
 71. Tomb RR, Nassar JS (2000) Profile of skin diseases observed in a department of dermatology (1995-2000). *Journal Medical Libanais* 48: 302-309.
 72. Sheno SD, Davis SV, Rao S, Rao G, Nair S (2005) Dermatoses among paddy field workers – A descriptive, cross-sectional pilot study. *Indian Journal of Dermatology Venereology and Leprology* 71: 254-258.
 73. El-Essawi D, Musial JL, Hammad A, Lim HW (2007) A survey of skin disease and skin-related issues in Arab Americans. *Journal of the American Academy Dermatology* 56: 933-8.
 74. Sivayathorn A (1995) Melasma in orientals. *Clinical Drug Investigation* 10: 34-40.
 75. Febrianti T, Sudharmono A, Rata IGAK, Bernadette I (2004) Epidemiologi melasma di Poliklinik Departemen Ilmu Kesehatan Kulit dan Kelamin RS dr. Cipto Mangunkusumo Jakarta tahun 2004. Perdoski [Internet]. Tersedia di: perdoski.org/index.php/public/information/mdvi-detai-content/86.
 76. Park HY, Yaar M (2012) Biology of melanocytes. In: Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffel DJ, Wolff K, eds. *Fitzpatrick's dermatology in general medicine*, 8th ed, vol 1. New York: Mc Graw Hill 765-781.
 77. Seiberg M (2001) Keratinocyte-melanocyte interactions during melanosome transfer. *European Society for Pigment Cell Research and the International Pigment Cell Society* 14: 236-242.
 78. Eberle AN (1988) Proopiomelanocortin and the melanocortin peptides. In: Eberle AN, Cone RD, eds. *The melanotropins: chemistry, physiology and mechanism of actions*. Basel: Karger Verlag 3-67.
 79. Mastore M, Kohler L, Nappi AJ (2005) Production and utilization of hydrogen peroxide associated with melanogenesis and tyrosinase-mediated oxidation of DOPA and dopamine. *Federation of European Biochemical Societies Journal*. 272: 2407-2415.
 80. Boissy RE (2003) Melanosome transfer to and translocation in the keratinocyte. *Experimental Dermatology* 12: 5-12.
 81. Lee ES, Kom JH, Im S, Lee KB, Sohn S, et al. (2001) Application of computerized image analysis in pigmentary skin disease. *International Journal of Dermatology* 40: 45-49.
 82. Hamed SH, Asaf SA, Amro B (2011) Innovative non-invasive technique in skin pharmaceuticals vs valid complements in cosmetic dermatology practice. *Jordan Journal of Pharmaceuticals Sciences* 4: 174-180.
 83. Devpura S, Pattamadilok B, Syed ZU, Vemulapalli P, Henderson M, et al. (2011) Critical comparison of diffuse reflectance spectroscopy and colorimetry as dermatological diagnostic tools for acanthosis nigricans: A chemometric approach. *Biomedical Optics Express* 2: 1664-1673.
 84. Jacques SL (2015) Quick analysis of optical spectra to quantify epidermal melanin and papillary dermal blood content skin. *J Biophotonics* 8: 309-316.
 85. Chatterjee M, Vasudevan B (2014) Recent advances in melasma. *Pigment International* 1: 70-80.
 86. Galeano J, Jolivot R, Marzani F, Benezeth Y (2012) Unmixing of human skin optical reflectance maps by non-negative matrix factorization algorithm. *National Electronics and Computer Technology Center* 10: 1-13.
 87. Hindritiani R (2015) Melasma. In: Wasitaatmadja SM, editor. *Pigmentasi kulit*. Jakarta: Badan Penerbit FKUI 114-126.
 88. Nikolaou V, Stratigos AJ, Katsambas AD (2006) Established treatments of skin hypermelanoses. *Journal of Cosmetic Dermatology* 5: 303-308.
 89. Ortonne JP, Bose SK (2005) Pigmentation: dyschromia. In: Baran R, Maibach HI, editor. *Textbook of cosmetic dermatology*. 3rd ed. London: Taylor&Francis 393-410.
 90. Ortonne JP (2006) Retinoid therapy of pigmentary disorders. *Dermatologic Therapy* 19: 280-288.
 91. Olumide YM, Akinkugbe AO, Altraide D, Mohammed T, Ahamefule M, et al. (2008) Complications of chronic use of skin lightening cosmetics. *International Journal of Dermatology* 47: 344-353.
 92. Lynde CB, Kraft JN, Lynde CW (2007) Topical treatment of melasma and postinflammatory hyperpigmentation. *Skin Therapy Letter* 1-12.
 93. Fisher AA (1982) Leukoderma from bleaching creams containing 2% hydroquinone. *Contact Dermatitis* 8: 272-273.
 94. Mann RJ, Harman RRM (1983) Nail staining due to hydroquinone skin-lightening creams. *British Journal of Dermatology* 108: 363-365.
 95. BPOM RI (2003) Kosmetik mengandung bahan berbahaya dan zat warna yang dilarang. Jakarta: BPOM RI.
 96. Rendon M, Cardona LM, Bussear EW, Benitez AL, Colon LE, et al. (2008) Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: A pilot study. *Cutis* 28: 372-378.
 97. Szkudlinski MW, Fremont V, Bonin C, Weintraub BD (2002) Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. *Physiological Review* 82: 473-502.
 98. Brownstein D (2010) 59 diseases now linked to thyroid imbalance, millions affected. *Newsmax Media* 3: 1-8.
 99. Slominski A (2005) Neuroendocrine system of the skin. *Dermatology* 211: 199-208.
 100. Slominski A, Wortsman J, Kohn L, Ain KB, Venkataraman GM, et al. (2002) Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. *Journal of Investigative Dermatology* 119: 1449-1455.
 101. Burman KD, McKinley GL (2006) Dermatologic aspects of thyroid disease. *Clinical Dermatology* 24: 247-55.
 102. Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. *Endocrine Reviews* 21: 457-87.
 103. Lee AY, Noh M (2013) The regulation of epidermal melanogenesis via cAMP and/or PKC signaling pathways: Insight for the development of hypopigmenting agents.

- Archive of Pharmacal Research 36: 792-801.
104. Braverman L, Wartofsky L (2010) Thyroid function tests. In: National Endocrine and Metabolic Disease Information Service. U.S Department of Health and Human Services NIH Publication No. 10-6284.
105. Tijn DA, Vijder JJM, Vulsma T (2008) Role of throtropin-releasing hormone stimulation test in diagnosis of congenital central hypotiroidism in infants. *Journal of Clinical Endocrinology & Metabolism* 93: 410-419.
106. Shankar K, Godse K, Aurangbadkar S, Lahiri K, Mysore V, et al. (2014) Evidence-based treatment for melasma: Expert opinion and a review. *Dermatologic Therapy* 4: 165-186.
107. Moncada B, Sanchez LKS, Alvarez BT, Cazares JPC, Ramirez JDM, et al. (2009) Molecular structure and concentration of melanin in the stratum corneum of patients with melasma. *Photodermatology, Photoimmunology & Photomedicine* 25: 159-160.
108. Malek J, Chedraoui A, Nikolic D, Baroutt N, Ghosn S, et al. (2013) Successful treatment of hydroquinone-resistant melasma using topical methimazole. *Dermatologic Therapy* 26: 69-72.
109. Kim H, Choi HR, Kim DS, Park KC (2012) Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action. *Annals of Dermatology* 24: 1-6.
110. Roy G, Muges G (2006) Bioinorganic chemistry in thyroid gland: Effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. *Bioinorganic Chemistry and Applications* 0: 1-9.
111. Taieb A, Andre MC, Briganti S, Picardo M (2011) Inhibitors and enhancers of melanogenesis. In: Riley PA, Borovansky J, editors. *Melanin and melanosomes biosynthesis, biogenesis, physiological, and pathological function*. Germany: Wiley-Blackwell 117-165.
112. Kasraee B, Ardekani GHS, Parhizgar A, Handjani F, Omrani GR, et al. (2008) Safety topical methimazole for the treatment of melasma. *Skin Pharmacology & Physiology* 21: 300-305.
113. Khani C, Hoffman C, Gropper C, Desai S (2014) Topical methimazole for the treatment of moderate to severe melasma. *American Osteopathic College of Dermatology Fall Meeting* 0: 96-101.
114. Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH (2010) Perkiraan besar sampel. In: Sastroasmoro S, Ismael S, editors. *Dasar-dasar metodologi penelitian klinis*. 3rd ed. Jakarta: Sagung Seto 302-331.
115. Kumari T, Prasad A, Sinha KK, Bharti MLG, Satyam K (2015) Age and specific thyroid hormone profile in euthyroid subjects. *Journal of Biochemical Technology* 6: 1008-1012.
116. Watanabe S (2014) Facial dermal melanocytosis. *Austin Journal of Dermatology* 1: 1-6.
117. Tranggono RIS, Adityarini (2010) Cosmeceuticals for Asian who are living in the tropics. *Journal of Applied Cosmetology* 28: 71-86.
118. Umborowati MA, Rahmadewi (2014) Studi Retrospektif: Diagnosis dan Terapi Pasien Melasma. *Berkala Ilmu Kesehatan Kulit dan Kelamin* 26: 56-63.
119. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, et al. (2006) Validation of a melasma quality of life questionnaire for Brazillian Portuguese language: The MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. *British Journal of Dermatology* 156: 13-20.
120. Verma K, Kumre K, Sharma H, Singh U (2015) A study of various etiological factors in the causation of melasma. *International Journal of Comparative Education and Development* 1: 28-32.
121. Damevska K (2014) New aspects of melasma. *Serbian Journal of Dermatology & Venereology* 6: 5-18.
122. Tamega AA, Miot LD, Bonfietti C, Gige TC, Marques ME, et al. (2013) Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. *Journal of European Academy Dermatology & Venereology* 27: 151-156.
123. Kaplan LA, Evans L, Monk C (2007) Effects of mothers' prenatal psychiatric status and postnatal caregiving on infant biobehavioral regulation: Can prenatal programming be modified?. *Early Human Development* 84:249-256.
124. Mimura C, Griffiths P (2004) A Japanese version of the perceived stress scale: Translation and preliminary test. *International Joournal of Neuronal System* 41: 379-385.
125. Cui S, Li Y, Lu H, Gao XH, Wei H, et al. (2016) Morphological relationship between nerve fibers and melanocytes in the epidermis of melasma. *Clinical Pediatric Dermatology* 2: 1-4.
126. Parsad D, Kumarasinge PW (2006) Psycho-social implications of pigmentary disorders in Asia. *Journal of Investagative Dermatology* 1-8.
127. Walker C (2005) Skin disease and psychology: a multitude of links. In: Walker C dan Papadopoulos L, editors. *Pshychodermatology the psychological impact of skin disorders*. New York: Cambridge University Press, Cambridge 1-14.

Copyright: ©2021 Frien Refla Syarif, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.